Drug Trial Radar · NCT07362355
The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
Last checked: Nov 20, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
340
Planned (sponsor's estimate)
Start
Feb 9, 2026
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SHR4640 tablets is a highly selective and potent URAT1 inhibitors. The study is being conducted to evaluate the efficacy, and safety of SHR4640 tablet combined with 40 mg/d febuxostat tablet in reducing uric acid in subjects with primary gout and hyperuricemia The primary purpose of the study is to evaluate the efficacy and safety of the combination of SHR4640 and 40 mg/d febuxostat compared with 60 mg/d febuxostat in primary gout and hyperuricemia subjects with inadequate control on 40 mg/d febuxostat for 12 weeks.
Conditions
- Primary Gout and Hyperuricemia
Interventions
SHR4640 ;FebuxostatDrug
SHR4640 high dose + Febuxostat
SHR4640 ; FebuxostatDrug
SHR4640 low dose + Febuxostat
SHR4640Drug
SHR4640 high dose
SHR4640Drug
SHR4640 low dose
FebuxostatDrug
Febuxostat
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects with serum uric acid levels of ≤360 μmol/L at week 12Time frame: at week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.